YUPELRI (revefenacin inhalation solution) Patient Assistance Program
Don’t let the high cost of brand nebulized LAMA therapy disrupt your COPD treatment. We help eligible patients access Yupelri (revefenacin inhalation solution) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Yupelri (revefenacin inhalation solution 175 mcg/3 mL) is FDA-approved for the maintenance treatment of patients with COPD. It is the first once-daily nebulized long-acting muscarinic antagonist (LAMA) — providing 24-hour bronchodilation from a single nebulization.
- Without assistance, Yupelri costs commonly run approximately $750–$900 per 30-vial supply (one month).
- Through AffordMyPrescriptions, qualifying patients can access Yupelri for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Yupelri in the U.S. as of 2026. Other LAMAs for COPD include tiotropium (Spiriva HandiHaler and Respimat — with generic Spiriva HandiHaler available), umeclidinium (Incruse Ellipta), aclidinium (Tudorza Pressair), glycopyrrolate (Seebri Neohaler, Lonhala Magnair nebulizer). Tiotropium is the most cost-effective LAMA for most patients who can use inhalers.
What Is Yupelri Prescription Assistance Program?
The Yupelri Prescription Assistance Program is a manufacturer-sponsored initiative that provides Yupelri at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for COPD patients who are uninsured or underinsured.
Navigating the program on your own means dealing with eligibility verification, pulmonology/primary care coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and renewal.
Pharmacy Price Comparison
- Without assistance, Yupelri costs roughly $750–$900/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$870 | Save ~$800/mo |
| CVS Pharmacy | ~$900 | Save ~$830/mo |
| Walmart | ~$780 | Save ~$710/mo |
| Costco | ~$770 | Save ~$700/mo |
Specialty Pharmacy | ~$800 | Save ~$730/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Yupelri Prescription Program?
The Patient Assistance Program is free to apply for and provides Yupelri at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Yupelri:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $750–$900 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Yupelri assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Yupelri Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Yupelri:
Yupelri (revefenacin) is a once-daily nebulized long-acting muscarinic antagonist (LAMA) used for maintenance bronchodilation in COPD. It was specifically designed as a once-daily nebulized LAMA — addressing the need for once-daily nebulized therapy in patients who cannot use handheld LAMA inhalers.
How Yupelri Works:
COPD bronchoconstriction occurs when acetylcholine binds to muscarinic M3 receptors on airway smooth muscle, causing contraction and narrowing. Revefenacin is a long-acting muscarinic antagonist (LAMA) that blocks these M3 receptors to prevent narrowing and provide 24-hour bronchodilation. Delivered once daily via a nebulizer, it offers an advantage over handheld inhalers for patients with poor inhaler technique, low inspiratory flow, cognitive impairment, or severe arthritis. However, the trade-off is the extra time and equipment burden required for nebulizer treatments.
Form and use:
Yupelri is administered once daily as a single 175 mcg/3 mL unit-dose vial. The medication must be inhaled using a standard jet nebulizer, with each treatment session lasting approximately 8 minutes. For consistency, patients should administer the dose at the same time every single day. Additionally, Yupelri should never be mixed with other nebulizer medications within the same nebulizer cup.
Generic availability:
As of 2026, there is no generic version of Yupelri available in the United States. Other LAMA options for COPD include umeclidinium, aclidinium, glycopyrrolate (which offers another nebulized option), and tiotropium, which has a generic version available for the HandiHaler. For patients who possess the ability to properly use handheld devices, generic Spiriva HandiHaler or alternative LAMA inhalers are typically more cost-effective than Yupelri.
Warnings:
Yupelri carries specific warnings for paradoxical bronchospasm, hypersensitivity reactions, and the worsening of acute angle-closure glaucoma. Due to the risk of urinary retention, it should be used with caution in patients with BPH or narrow-angle glaucoma, and avoided by those with severe sensitivities to similar drugs. As a LAMA, this medication is not intended for asthma treatment or for the relief of acute bronchospasm. Because revefenacin has limited systemic absorption, its drug interactions remain minimal.
FAQ (Frequently Asked Questions)
How Much Does Yupelri Cost Without Insurance?
Yupelri costs approximately $750–$900 per 30-vial monthly supply. Through AffordMyPrescriptions, qualifying patients receive Yupelri at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Was Yupelri Prescribed Instead Of Spiriva Or Incruse?
Yupelri’s main advantage is once-daily nebulized delivery — useful for patients who cannot effectively use handheld LAMA inhalers (HandiHaler dry-powder requires adequate inspiratory flow; Respimat soft mist requires coordination). If you can use a handheld LAMA inhaler well, options like generic tiotropium (Spiriva HandiHaler) or Incruse Ellipta are typically more cost-effective. Discuss with your pulmonologist whether Yupelri’s nebulized format is necessary for your situation.
How Long Does The Nebulization Take?
Yupelri takes approximately 8 minutes per nebulization, using a standard jet nebulizer. This is longer than the few seconds required for handheld inhalers — but allows medication delivery in patients who cannot use inhalers effectively.
Can I Use Yupelri With My Albuterol?
Yes — many COPD patients use Yupelri (long-acting LAMA) for maintenance plus albuterol (short-acting beta-agonist) for rescue use during acute symptoms. These work by different mechanisms (LAMA: blocks cholinergic constriction; SABA: activates beta-2 to relax muscle) and complement each other. Don’t mix Yupelri and albuterol in the same nebulizer cup unless your prescriber confirms compatibility — run them sequentially.
Why Use Yupelri Instead Of A LABA/LAMA Inhaler Combination?
Many COPD patients benefit from combined LABA + LAMA therapy (Anoro Ellipta, Stiolto Respimat, Bevespi Aerosphere). If you have access to use these inhalers well, combination LABA/LAMA may be more convenient (single inhaler) and similarly effective. Yupelri is a single-class agent (LAMA only); some patients also need a LABA. Discuss the optimal regimen with your pulmonologist.
What If I Have Glaucoma Or An Enlarged Prostate?
Tell your pulmonologist. LAMAs can worsen narrow-angle glaucoma and urinary retention from benign prostatic hyperplasia (BPH). Mild BPH usually does not preclude LAMA use, but discuss before starting. Tell your prescriber about new eye pain (could indicate acute angle-closure glaucoma) or urinary difficulty.
What If My Application Is Denied?
If denied, we explore alternatives — switching to generic tiotropium (Spiriva HandiHaler) if you can use a dry-powder inhaler, glycopyrrolate (Lonhala Magnair nebulizer), Incruse Ellipta, or a LABA/LAMA combination inhaler, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the COPD Foundation, American Lung Association, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Yupelri, our team may be able to help you access assistance programs — or guide you to generic tiotropium or another LAMA option. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.